EGFR and neoplasm: Thus, in patients whose cancer progresses on treatment and are consequently taken off therapy, residual tumor cells that lack the proliferation-compromising resistance mechanism (EGFR expression in this case) may have a selective growth advantage, leading to their enrichment as a dominant clone within the relapsed tumor.